32 results
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
and extensive Phase 3 clinical trials.
For each clinical trial, an independent IRB or independent ethics committee, covering each site proposing to conduct
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
rigorous and extensive Phase 3 clinical trials.
For each clinical trial, an independent IRB or independent ethics committee, covering each site proposing
8-K
EX-99.1
za2yee3p9zv5gc
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
u2eae ag49au3m
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
424B5
70sqzgpuauocwn6ukk
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
vxw94x3 sydhgjw75
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
ehn0zb8crrkb0v
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
oc31ubuo ihk
23 Jun 20
Prospectus supplement for primary offering
4:06pm